Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. Hara T, et al. Among authors: mabuchi r. Hematol Oncol. 2018 Oct;36(4):638-644. doi: 10.1002/hon.2524. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882279 Clinical Trial.
Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
Goto N, Tsurumi H, Takemura M, Matsumoto T, Shibata Y, Mabuchi R, Nakamura N, Nakamura H, Yamada T, Seishima M, Takami T, Takeuchi T, Moriwaki H. Goto N, et al. Among authors: mabuchi r. J Clin Exp Hematop. 2014;54(2):117-27. doi: 10.3960/jslrt.54.117. J Clin Exp Hematop. 2014. PMID: 25318944 Free article. No abstract available.
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y, Hara T, Kasahara S, Yamada T, Sawada M, Mabuchi R, Matsumoto T, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Kito Y, Goto N, Miyazaki T, Takami T, Takeuchi T, Shimizu M, Tsurumi H. Shibata Y, et al. Among authors: mabuchi r. Hematol Oncol. 2017 Jun;35(2):163-171. doi: 10.1002/hon.2262. Epub 2015 Oct 9. Hematol Oncol. 2017. PMID: 26449182
Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N, Kanemura N, Shibata Y, Matsumoto T, Mabuchi R, Nakamura H, Kitagawa J, Goto N, Hara T, Tsurumi H, Moriwaki H. Nakamura N, et al. Among authors: mabuchi r. Leuk Lymphoma. 2014 Jul;55(7):1691-3. doi: 10.3109/10428194.2013.853300. Epub 2014 Jan 28. Leuk Lymphoma. 2014. PMID: 24138307 No abstract available.
Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
Nakamura N, Hara T, Shimizu M, Mabuchi R, Nagano J, Ohno T, Kochi T, Kubota M, Shirakami Y, Goto N, Ito H, Saito K, Tanaka T, Moriwaki H, Tsurumi H. Nakamura N, et al. Among authors: mabuchi r. Int J Hematol. 2015 Sep;102(3):327-34. doi: 10.1007/s12185-015-1835-8. Epub 2015 Aug 5. Int J Hematol. 2015. PMID: 26243621
31 results